Azitra is trading 5.31% down at $0.13 on October 1, 2026; no clear same-direction catalyst was identified.
- The company said its ATR04-484 Phase 1/2 trial will proceed to Cohort 2 after a safety review of Cohort 1 data. This positive update does not explain the decline.
- Broad market indices were modestly higher, and no trading-volume information was found.
- The supplied price context was used; external quotes differ and were not used for price data.